User login
Key clinical point: Women with lymph-node positive early breast cancer (BC) had a high risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), particularly if they were older or receiving anthracycline treatment.
Major finding: The cumulative incidence of CTR-CVT was 71.8%, with 54.0% of events occurring in patients who were 51-60 years old. Similarly, anthracycline treatment was associated with 51.0% of hypertension, 57.0% of coronary artery disease, 60.0% of heart failure, and 54.0% of atrial fibrillation events.
Study details: Findings are from a retrospective population-based cohort study including 433 women age <60 years with lymph node-positive early BC, of which 53.0%, 18.0%, and 29.0% of women received anthracycline, non-anthracycline-containing chemotherapy, and no chemotherapy, respectively.
Disclosures: This study was supported by the Stockholm County Council and other sources. Three authors declared receiving research funding, payments for traveling and accommodation, or lecture fees from various sources.
Source: Hubbert L et al. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: A Swedish cohort study. Front Oncol. 2023;13:1095251 (Apr 19). Doi: 10.3389/fonc.2023.1095251
Key clinical point: Women with lymph-node positive early breast cancer (BC) had a high risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), particularly if they were older or receiving anthracycline treatment.
Major finding: The cumulative incidence of CTR-CVT was 71.8%, with 54.0% of events occurring in patients who were 51-60 years old. Similarly, anthracycline treatment was associated with 51.0% of hypertension, 57.0% of coronary artery disease, 60.0% of heart failure, and 54.0% of atrial fibrillation events.
Study details: Findings are from a retrospective population-based cohort study including 433 women age <60 years with lymph node-positive early BC, of which 53.0%, 18.0%, and 29.0% of women received anthracycline, non-anthracycline-containing chemotherapy, and no chemotherapy, respectively.
Disclosures: This study was supported by the Stockholm County Council and other sources. Three authors declared receiving research funding, payments for traveling and accommodation, or lecture fees from various sources.
Source: Hubbert L et al. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: A Swedish cohort study. Front Oncol. 2023;13:1095251 (Apr 19). Doi: 10.3389/fonc.2023.1095251
Key clinical point: Women with lymph-node positive early breast cancer (BC) had a high risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), particularly if they were older or receiving anthracycline treatment.
Major finding: The cumulative incidence of CTR-CVT was 71.8%, with 54.0% of events occurring in patients who were 51-60 years old. Similarly, anthracycline treatment was associated with 51.0% of hypertension, 57.0% of coronary artery disease, 60.0% of heart failure, and 54.0% of atrial fibrillation events.
Study details: Findings are from a retrospective population-based cohort study including 433 women age <60 years with lymph node-positive early BC, of which 53.0%, 18.0%, and 29.0% of women received anthracycline, non-anthracycline-containing chemotherapy, and no chemotherapy, respectively.
Disclosures: This study was supported by the Stockholm County Council and other sources. Three authors declared receiving research funding, payments for traveling and accommodation, or lecture fees from various sources.
Source: Hubbert L et al. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: A Swedish cohort study. Front Oncol. 2023;13:1095251 (Apr 19). Doi: 10.3389/fonc.2023.1095251